| Multiparticulate modified release composition GSR JG. Devane, NMM Fanning, P Stark US Patent 6,793,936, 2004 | 562* | 2004 |
| Multiparticulate modified release composition GSR JG. Devane, NMM Fanning, P Stark US Patent 6,730,325, 2004 | 518* | 2004 |
| Multiparticulate modified release composition GSR JG. Devane, NMM Fanning, P Stark US Patent 6,228,398, 2001 | 467 | 2001 |
| Multiparticulate modified release composition GSR JG. Devane, NMM Fanning, P Stark US Patent US1999/025,632, 2000 | 467* | 2000 |
| Methods to compare dissolution profiles and a rationale for wide dissolution specifications for metoprolol tartrate tablets JE Polli, GS Rekhi, LL Augsburger, VP Shah Journal of pharmaceutical sciences 86 (6), 690-700, 1997 | 465 | 1997 |
| Ethylcellulose-a polymer review GS Rekhi, SS Jambhekar Drug development and industrial pharmacy 21 (1), 61-77, 1995 | 227 | 1995 |
| Multiparticulate modified release composition J Devane, P Stark, N Fanning, G Rekhi, S Jenkins, G Liversidge US Patent App. 11/372,857, 2006 | 212 | 2006 |
| Multiparticulate modified release composition JG Devane, P Stark, NMM Fanning, GS Rekhi US Patent 6,902,742, 2005 | 199 | 2005 |
| Identification of critical formulation and processing variables for metoprolol tartrate extended-release (ER) matrix tablets GS Rekhi, RV Nellore, AS Hussain, LG Tillman, HJ Malinowski, ... Journal of controlled release 59 (3), 327-342, 1999 | 156 | 1999 |
| Development of metoprolol tartrate extended-release matrix tablet formulations for regulatory policy consideration RV Nellore, GS Rekhi, AS Hussain, LG Tillman, LL Augsburger Journal of controlled release 50 (1-3), 247-256, 1998 | 142 | 1998 |
| Methods to compare dissolution profiles JE Polli, GS Rekhi, VP Shah Drug Information Journal 30 (4), 1113-1120, 1996 | 82 | 1996 |
| Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone JG Devane, P Stark, N Fanning, GS Rekhi, SA Jenkins, G Liversidge US Patent App. 11/768,169, 2008 | 76 | 2008 |
| Compositions comprising nanoparticulate naproxen and controlled release hydrocodone JG Devane, P Stark, N Fanning, GS Rekhi, SA Jenkins, G Liversidge US Patent App. 11/768,154, 2008 | 63 | 2008 |
| Evaluation of in vitro release rate and in vivo absorption characteristics of four metoprolol tartrate immediate-release tablet formulations GS Rekhi, ND Eddington, MJ Fossler, P Schwartz, LJ Lesko, ... Pharmaceutical Development and Technology 2 (1), 11-24, 1997 | 57 | 1997 |
| Multiparticulate modified release composition J Devane, P Stark, N Fanning, GS Rekhi US Patent App. 10/827,689, 2004 | 55 | 2004 |
| Nanoparticulate and controlled release compositions comprising Cefditoren JG Devane, P Stark, NMN Fanning, GS Rekhi, SA Jenkins, G Liversidge US Patent 8,119,163, 2012 | 53 | 2012 |
| A simple and rapid liquid chromatographic method for the determination of major metabolites of sulfasalazine in biological fluids VS Chungi, GS Rekhi, L Shargel Journal of pharmaceutical sciences 78 (3), 235-238, 1989 | 53 | 1989 |
| Evaluation of “external” predictability of an in vitro–in vivo correlation for an extended‐release formulation containing metoprolol tartrate H Mahayni, GS Rekhi, RS Uppoor, P Marroum, AS Hussain, ... Journal of pharmaceutical sciences 89 (10), 1354-1361, 2000 | 51 | 2000 |
| Identification of formulation and manufacturing variables that influence in vitro dissolution and in vivo bioavailability of propranolol hydrochloride tablets ND Eddington, M Ashraf, LL Augsburger, JL Leslie, MJ Fossler, LJ Lesko, ... Pharmaceutical development and technology 3 (4), 535-547, 1998 | 51 | 1998 |
| Factors affecting the release of propranolol hydrochloride from beads coated with aqueous polymeric dispersions GS Rekhi, SC Porter, SS Jambhekar Drug development and industrial pharmacy 21 (6), 709-729, 1995 | 48 | 1995 |
Ajaz S. Hussain, Ph.D.Insight, Advice & SolutionsVerified email at valgenesis.com
